- Arrambide, Georgina|||0000-0002-2657-5510
- Espejo, Carmen|||0000-0001-9949-5901
- Eixarch, Herena|||0000-0001-7525-9533
- Villar, Luisa M.|||0000-0002-9067-3668
- Alvarez-Cermeño, José C.|||0000-0002-1345-2837
- Picón, Carmen
- Kuhle, Jens|||0000-0002-6963-8892
- Disanto, Giulio
- Kappos, Ludwig|||0000-0003-4175-5509
- Sastre-Garriga, Jaume|||0000-0002-1589-2254
- Pareto, Deborah|||0000-0001-7356-3769
- Simon, Eva
- Comabella López, Manuel|||0000-0002-2373-6657
- Río, Jordi|||0000-0003-4546-7627
- Nos, Carlos|||0000-0002-3830-4910
- Tur, Carmen|||0000-0003-1849-3184
- Castilló, Joaquín|||0000-0002-8951-6315
- Vidal-Jordana, Angela|||0000-0002-7270-5507
- Galan, Ingrid|||0000-0001-5774-4260
- Arévalo, María Jesús|||0000-0003-0626-5555
- Auger, Cristina|||0000-0001-9846-4767
- Rovira, Alex|||0000-0002-2132-6750
- Montalban, Xavier|||0000-0002-0098-9918
- Tintoré, Mar|||0000-0001-9999-5359
To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (r = -0.892) and percentage brain volume change (r = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.